Digital health platform Noom is pivoting its marketing strategy to emphasize behavioral psychology as a differentiator against the backdrop of the rising popularity of GLP-1 weight-loss medications. The company’s new “Lose For Keeps” campaign, featuring actor Rebel Wilson, positions its coaching-led model as a long-term solution for patients using or considering weight-management drugs.
Positioning Behavioral Psychology Against GLP-1 Demand
The weight-loss market has shifted significantly since the widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide.
Noom is responding to this trend by framing its existing platform—which centers on cognitive behavioral therapy (CBT) and human coaching—as a necessary companion to pharmacological treatment. Chief Brand Officer Rachel Mahoney stated that the campaign is designed to "put our flag down in the conversation" and clarify the company’s value proposition in a crowded digital health landscape. By focusing on "behavioral change," Noom aims to target users who are concerned about weight regain after stopping medication, a common clinical consideration for patients on long-term GLP-1 therapies.
The Evolution of the Noom Business Model
The current strategy represents a departure from the company’s earlier purely diet-focused messaging.
Market Context and Competitive Strategy
The "Lose For Keeps" campaign, developed in collaboration with the agency Mekanism, arrives as Noom faces intense competition from both legacy weight-loss programs and new digital entrants that provide direct access to GLP-1 prescriptions.
| Feature | Traditional Diet Programs | GLP-1 Specialized Platforms | Noom (Current Strategy) |
|---|---|---|---|
| Primary Driver | Calorie restriction | Pharmacological intervention | Behavioral psychology + Coaching |
| Long-term Focus | Habit formation | Medication management | Sustainable lifestyle maintenance |
| Integration | Minimal | High | Hybrid (Medication + Coaching) |
Noom’s future performance will likely depend on whether this behavioral-first approach provides the clinical outcomes that patients and healthcare providers now demand in the era of GLP-1 treatments.